At the EBMT General Assembly in Florence 2025, the proposal to establish a JACIE Working Party (WP) was formally approved. Since then, efforts have been underway to transition JACIE from its previous committee structure into full Working Party status. This important work is being led by the first elected JACIE WP Chair, Dr Lynn Manson from Scotland.
As part of the preparations, discussions have focused on defining the scope of the new WP. While JACIE remains fundamentally a quality assurance organisation, its transition to WP status brings a new emphasis on scientific output—aligning with the broader EBMT strategy and the role of other Working Parties. Although JACIE has previously contributed to several publications, these were typically isolated initiatives. The new WP aims to integrate scientific research more systematically alongside its established operational assurance work.
This scientific development will be overseen by the WP Board led by Dr Lynn Manson and supported by the newly appointed WP Secretary, Dr Richard Olaussen from Norway. Dr Olaussen is a senior consultant at the Department of Oncology, Section for Cellular Therapy, Oslo University Hospital. He has served as a JACIE Inspector since 2015 and is the current National Representative for Norway. He is a member of the Processing Sub-Committee for the 9th Edition Standards development.
The JACIE WP will also oversee the existing Committees—Assurance, Inspector, and Quality Management—as well as the National Representatives Forum, with all Committee Chairs sitting on the WP Board. Additionally, the EBMT Executive Committee has approved the integration of the Clinical Outcomes Group (Benchmarking initiative), led by Prof John Snowden, under the strategic leadership of the new WP.
The JACIE WP structure will also allow for the creation of Task & Finish groups and other sub-groups as needed, enabling flexibility as the WP expands its activities.
Full implementation of the new JACIE Working Party structure is expected from August 2025.